Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study

Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study

Abstract Background Combination of gemcitabine and nab-paclitaxel has superior clinical efficacy than gemcitabine alone. Nevertheless, health-related quality of life. (QoL) associated with this combination therapy when administered at first-line in advanced pancreatic adenocarcinoma is unknown. Meth...

Full description

Bibliographic Details
Main Authors: Suayib Yalcin, Faysal Dane, Berna Oksuzoglu, Nuriye Yildirim Ozdemir, Abdurrahman Isikdogan, Metin Ozkan, Guzin Gonullu Demirag, Hasan Senol Coskun, Bulent Karabulut, Turkkan Evrensel, Mehmet Ali Ustaoglu, Feyyaz Ozdemir, Hande Turna, Tugba Yavuzsen, Faruk Aykan, Alper Sevinc, Hakan Akbulut, Deniz Yuce, Mutlu Hayran, Saadettin Kilickap
Format: Article
Language:English
Published: BMC 2020-03-01
Series:BMC Cancer
Subjects:
Nab-paclitaxel
Gemcitabine
Pancreatic cancer
Metastatic
Quality of life
Online Access:http://link.springer.com/article/10.1186/s12885-020-06758-9

Internet

http://link.springer.com/article/10.1186/s12885-020-06758-9

Similar Items